Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

NICE expands Merck KGaA’s Erbitux reach

Backs the medicines use for patients with SCCHN

- PMLiVE

Roivant gets $1.1bn investment from Japan’s SoftBank

The fund will launch new subsidiaries, says the biotech

Roche Basel Switzerland

Ocrevus off to a flying start as Roche raises 2017 forecasts

New multiple sclerosis drug posts positive results in first quarter

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Merck’s new health charity strikes partnership deal with Tanzania

The Merck Foundation will support oncology fellowship programmes for Tanzanian doctors

- PMLiVE

Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010

- PMLiVE

Taking a lean and careful approach

Kunwar Shailubhai on why biotech is a roller coaster and how Tiziana Life Sciences is pursuing its mission to tackle unmet needs

- PMLiVE

Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Analysts predict it will bring in sales of around $600m by 2020

- PMLiVE

Fresenius Kabi buys Akorn and Merck’s biosimilar businesses

German-based firm predicts savings after it unites the two biopharma companies

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

- PMLiVE

Dr Reddy’s brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links